NASDAQ:NITE - Nightstar Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$25.41
+0 (0.00%)
Get New Nightstar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NITE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NITE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Nightstar Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $25.41.

This chart shows the closing price for NITE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Nightstar Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2019BarclaysDowngradeOverweight ➝ Equal Weight$28.00 ➝ $26.00Low
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$25.18Low
3/5/2019MizuhoDowngradeBuy ➝ Neutral$22.00 ➝ $25.50High
3/5/2019UBS GroupDowngradeBuy ➝ Neutral$21.00 ➝ $25.50High
3/4/2019Chardan CapitalReiterated RatingBuy ➝ BuyLow
3/4/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$41.00 ➝ $25.50Low
3/4/2019WedbushDowngradeOutperform ➝ NeutralLow
3/4/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$42.00 ➝ $25.50High
2/26/2019Cantor FitzgeraldReiterated RatingBuy$42.00High
1/31/2019Cantor FitzgeraldReiterated RatingBuy$42.00Medium
1/10/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$36.00 ➝ $42.00High
1/4/2019UBS GroupInitiated CoverageBuy ➝ Buy$21.00High
12/17/2018BarclaysInitiated CoverageOverweight ➝ Overweight$28.00High
10/11/2018Cantor FitzgeraldInitiated CoverageOverweight$36.00High
9/25/2018WedbushReiterated RatingOutperform$31.00Medium
9/25/2018MizuhoReiterated RatingBuy$24.00Medium
9/24/2018BMO Capital MarketsSet Price TargetBuy$41.00High
9/24/2018SVB LeerinkBoost Price TargetOutperform ➝ Positive$30.00 ➝ $35.00High
9/4/2018MizuhoBoost Price TargetPositive ➝ Buy$24.00Medium
8/22/2018Janney Montgomery ScottInitiated CoverageBuy$34.00Medium
8/14/2018MizuhoReiterated RatingBuy$20.00Medium
6/27/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
6/6/2018Chardan CapitalReiterated RatingBuy$40.00Low
4/27/2018MizuhoReiterated RatingBuy$20.00Medium
4/5/2018WedbushReiterated RatingOutperform$31.00High
4/5/2018MizuhoReiterated RatingBuy$20.00High
3/7/2018WedbushReiterated RatingOutperform$31.00Low
2/27/2018MizuhoInitiated CoverageBuy$20.00High
1/17/2018WedbushReiterated RatingOutperform ➝ Outperform$29.00 ➝ $31.00Low
1/3/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
10/23/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00N/A
10/23/2017WedbushInitiated CoverageOutperform ➝ Outperform$19.00N/A
10/23/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$25.00N/A
10/23/2017BMO Capital MarketsInitiated CoverageOutperform$30.00N/A
(Data available from 8/16/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Nightstar Therapeutics logo
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $25.41
Low: $25.41
High: $25.41

50 Day Range

MA: $25.41
Low: $25.41
High: $25.41

52 Week Range

Now: $25.41
Low: $9.59
High: $29.55

Volume

40 shs

Average Volume

185,808 shs

Market Capitalization

$852.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Nightstar Therapeutics?

The following equities research analysts have issued stock ratings on Nightstar Therapeutics in the last year:
View the latest analyst ratings for NITE.

What is the current price target for Nightstar Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Nightstar Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Nightstar Therapeutics in the next year.
View the latest price targets for NITE.

What is the current consensus analyst rating for Nightstar Therapeutics?

Nightstar Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NITE.

What other companies compete with Nightstar Therapeutics?

How do I contact Nightstar Therapeutics' investor relations team?

Nightstar Therapeutics' physical mailing address is 10 MIDFORD PLACE 2ND FLOOR, LONDON X0, W1T5BJ. The company's listed phone number is 44-20-7062-2777 and its investor relations email address is [email protected] The official website for Nightstar Therapeutics is www.nightstartx.com. Learn More about contacing Nightstar Therapeutics investor relations.